Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy.
To test the hypothesis that systemic administration of immunoglobulin might reduce glomerular injury in membranous nephropathy through mechanisms involving inhibition of complement activation, we studied the passive Heymann nephritis (PHN) model of membranous nephropathy in rats. The daily administration of immunoglobulin goat IgG (600 mg/kg i.p.) reduced proteinuria by 52%. Quantitative immunohistochemical analysis showed that the glomerular deposition of C3c, an indicator of ongoing complement attack, and of C5b-9 was significantly decreased in the immunoglobulin treated group, while deposition of anti-Fx1A was not affected. Electron microscopic analysis demonstrated that the extent of subepithelial immune complexes did not appreciably differ between treated and control animals. Systemic complement levels were not altered by immunoglobulin treatment. These data suggest that the reduction in proteinuria that resulted from systemic immunoglobulin administration was mediated by modifying the effect of complement induced glomerular injury. This interpretation was further supported by in vitro data that documented a significant reduction in C5b-9 induced glomerular epithelial cell lysis in the presence of both goat and rat IgG. These results indicate that systemic administration of immunoglobulin can substantially reduce ongoing complement activation in the glomerulus in PHN rats and that this effect is associated with a significant reduction in glomerular injury.
Nangaku
M
M
Department of Medicine, University of Washington, Seattle, USA.
Pippin
J
J
Richardson
C A
CA
Schulze
M
M
Young
B A
BA
Alpers
C E
CE
Gordon
K L
KL
Johnson
R J
RJ
Couser
W G
WG
D000818:Animals; D015938:Complement Membrane Attack Complex / Q000652:urine; D005921:Glomerulonephritis / Q000473:pathology / Q000628:therapy*; D006041:Goats; D007074:Immunoglobulin G / Q000097:blood / Q000627:therapeutic use*; D007678:Kidney Glomerulus / Q000648:ultrastructure; D008297:Male; D011507:Proteinuria / Q000628:therapy; D051381:Rats; D017207:Rats, Sprague-Dawley
D015938:Complement Membrane Attack Complex; D007074:Immunoglobulin G